ImmuPharma Sponsors the 2014 European Lupus Confer

RNS Number : 5939E

Immupharma PLC

11 April 2014

 

FOR IMMEDIATE RELEASE RNS REACH                                                                                             11 APRIL 2014

ImmuPharma Sponsors the 2014 European Lupus Conference

Presentation Date: 24 April 2014

ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that it is sponsoring the forthcoming European Lupus Conference which takes place in Athens, Greece from April 23 - 26, 2014.

The "European Lupus Meetings" is a major forum for all people interested in the disease: with approximately 800 physicians of various disciplines (internal medicine, rheumatology, nephrology, dermatology, obstetrics and gynecology, neurology), health professionals, regulatory agencies, pharmaceutical industry and patient representatives.

ImmuPharma recently had confirmation from Dr. Sylviane Muller, Research Director at CNRS, Strasbourg, France and the key inventor of Lupuzor, that she has been invited to present at the conference.  Her talk is planned  in the Basic and Translational Symposium (15-16.30pm CET) on Thursday April 24.  The title of the session is called "A novel way of immunomodulation in lupus".  Her presentation will focus partly on the on the highly competitive and efficacious mode of mechanism of Lupuzor^TM, ImmuPharma'spotential blockbuster drug for Lupus, a chronic autoimmune disease. Lupuzor^TM has received Special Protocol Assessment and Fast Track Designation from the FDA for a Phase III trial.

Also in attendance at the conference will be two of ImmuPharma's eminent 'Scientific Advisory Board', Dr. Daniel J. Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, and a leading practitioner within the field of Lupus, andProf. Cees GM Kallenberg, M.D., Ph.D. Prof. Department of Rheumatology and Clinical Immunology, University Medical Center Groningen who is a member of  the 'European Organisation Committee' for this forthcoming Lupus meeting. (Full biographies can be found in 'Notes to Editors').

Details of the presentation given by Dr. Slyvianne Muller will be provided by ImmuPharma following the conference.

 For further information please contact:

ImmuPharma PLC  (www.immupharma.com)
Dimitri Dimitriou, Chief Executive Officer	[phone]
Richard Warr, Chairman	[phone]
Lisa Baderoon, Head of Investor Relations	[phone]
Panmure Gordon & Co	[phone]
Hugh Morgan, Fred Walsh

Notes to Editors

ImmuPharma

ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need.  ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents.  The Company's most advanced drug candidate, Lupuzor^TM a potential blockbuster drug for Lupus, a chronic autoimmune disease has received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation.  Most recent news confirmed a five year £50m funding facility from Darwin Strategic and the establishment of a Scientific Advisory Board to provide scientific advice and support for Lupuzor's pivotal phase III programme.  ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. www.immupharma.com

Dr. Sylviane Muller, Research Director at CNRS & Co-founder of ImmuPharma France

Sylviane Muller is Professor at the Institute for Advanced Study of the University of Strasbourg (USIAS), holder of the chair of immunology and therapeutic chemistry, Distinguished class Research Director  and head of the 'Immunologie et chimie thérapeutiques' unit of the "Centre National de la Recherche Scientifique" (CNRS), the largest fundamental research organization in  Europe. She obtained her PhD at the University of Strasbourg. For two years, she was a post-doctoral fellow in Freiburg (Germany) at the Max-Planck Institute for Immunobiology. Her field of expertise covers autoimmunity, immuno-peptides and synthetic vaccines. She has made 23 patented discoveries and is widely published (330 publications and reviews/chapters). She was also a founder of Neosystem, now Polypeptide-France, a leading peptide development and manufacturing company. She is the key inventor of ImmuPharma's Lupus lead drug candidate Lupuzor and has been working in this field for more than ten years.

Dr. Daniel J Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles
Dr Wallace received his undergraduate and medical education at the University of Southern California, graduating with an MD in 1974. His graduate medical training included an internship at Brown University in Providence, Rhode Island, medical residency at Cedars-Sinai Medical Center in Los Angeles and a fellowship in rheumatology at UCLA. He is Board Certified in both Internal Medicine and Rheumatology.

 While a fellow at UCLA, he conducted pioneering arthritis research that landed his picture in Time magazine and developed a close relationship with his mentor, Edmund Dubois. Dr Dubois had the largest lupus practice in the United States at the time and was the principal editor of the only lupus textbook. He is the author of 6 medical textbooks (including the last 4 editions of Dubois' Lupus Erythematosus, All About Fibromyalgia, The Lupus Book, All About Osteoarthritis, The New Sjogren's Syndrome Handbook, and Fibromyalgia & Other Central Pain Syndromes), 19 book chapters, and over 250 medical publications. The latter have appeared in the New England Journal of Medicine, Annals of Internal Medicine, the Lancet, Journal of Clinical Investigation, Journal of Immunology, and Journal of the American Medical Association. Wallace's academic efforts include having served as Chief of Rheumatology at Cedars-Sinai Medical Center, Century City Hospital, and the City of Hope Medical Center in Duarte, CA. He is currently a Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA. His clinical practice is based at Cedars-Sinai, where he is involved in the care of 2,000 lupus patients, the largest practice of its kind in the United States. The Wallace Rheumatic Disease Research Center currently runs over 30 clinical trials for patients with rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis and fibromyalgia.

The center has been the recipient of 3 National Institute of Health grants. 20% of his time is spent in teaching and research, providing free medical care.

Prof. Cees GM Kallenberg, M.D., Ph.D. (Netherlands) - Professor, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen

Professor Cees GM Kallenberg received his medical training at the Medical School of the University of Leiden, The Netherlands. After getting his degree as an MD in 1972, he got additional training in surgery and served as a military MD in the Dutch Army. In 1975 he started his training as a resident in Internal Medicine at the Groningen University Hospital and was registered as internist in 1980. He worked as an internist and finished his PhD studies on the subject 'Raynaud's phenomenon and Systemic Autoimmune Disease' successfully in 1982. He further trained in immunology and medical immunology and was registered as immunologist and medical immunologist. He was appointed as associate professor in Internal Medicine - Clinical Immunology in 1985 and as a full professor in 1993.

He has written more than 500 articles in international peer-reviewed journals, gives lectures as an invited speaker on his research topics on all major international meetings, and is an editorial board member of several journals in clinical immunology, nephrology and rheumatology.

About the Euopean Lupus Meeting : 2014

The 9th Eurolupus Meeting will be held in Athens Greece from April 23rd to April 26th 2014. This is the premier European Lupus Meeting with approximately 800 physicians of various disciplines (internal medicine, rheumatology, nephrology, dermatology, obstetrics and gynecology, neurology), nurses and patients.

The scientific program includes basic, translational and clinical sessions as well as original research to be presented by an international faculty of opinion leaders in lupus. In addition to the main program, there will be a program for patients coordinated by Lupus Europe, the European lupus patient organization.

Attendees come to the meeting to be updated in the latest developments, including the products, services and treatments available in the marketplace. The meeting also includes satellite symposia and other lupus-related educational and promotional activities. www.lupus2014.org

 

END

 

 

NRALLFSTSLIILIS